Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Revenue 25,774.09 22,753.12 21,763.34 19,159.59 ...

Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product and Trump tariff pressure has impacted the ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries, including ...

Cold showers offer many benefits, including increasing endorphins, improving metabolism, and enhancing circulation. They may also help fight off common illnesses, like colds and flus. Cold showers ...

Return on investment - most recent fiscal year 16.16 ...

Cold noses are not uncommon and they typically resolve on their own, though cold noses can occur with specific health conditions. These include underlying thyroid and heart conditions, as well as cold ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

5,504 crore for the quarter ended June, which was also sharply higher than analysts’ expectations. Cipla Q1 Results: Cons PAT rises 18% YoY to Rs 1,178 crore, beats estimates Cipla Q1 Results: The ...